LH:NYSELabcorp Holdings Inc. Analysis

Labcorp’s price sits below its 20‑day SMA (281) and 50‑day SMA (271), with the RSI at 41 indicating neutral momentum, while a bearish MACD histogram and declining volume suggest short‑term pressure. The 30‑day volatility of roughly 26% and a beta under 1 point to moderate price swings, and the Fear & Greed Index’s “Extreme Greed” label reflects strong market appetite despite these technical headwinds.
Fundamentally, revenue grew 5.6% YoY to $3.52 B in Q4, margins remain modest (gross 28.8%, operating 10.5%), and the company announced a $0.72 quarterly dividend (annual 1.05% yield). However, a high debt‑to‑equity ratio of 75.6% and a DCF fair value of $134 versus the current $269 price flag a significant valuation gap, even though forward earnings imply a lower PE of 13.9. Recent guidance of $14.7 B for FY2026 aligns with analyst expectations, supporting a medium‑term upside of about 14%.